Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Bryan J. McVerry, Andreas M. Schmitt et al.|Nature Communications|2021Cited by 295
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunityJulia Niessl, Daniel E. Kaufmann, Marina Caskey et al.|Nature Medicine|2020Cited by 164
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 studyYehuda Z. Cohen, Marina Caskey, Allison L. Butler et al.|PLoS ONE|2019Cited by 92
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 PreventionLindsey R. Baden, Etienne Karita, Gaudensia Mutua et al.|Annals of Internal Medicine|2016Cited by 84
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trialsCathrine Axfors, Bryan J. McVerry, Andreas M. Schmitt et al.|medRxiv|2020Cited by 79